Board of Cronin Group Plc
Mark Warne became Executive Chairman of Cronin Group Plc in April 2017. He is also Head of IP Group's Healthcare division, which at the end of December 2016, had shareholdings in 27 companies valued at over £330 million. Dr Warne represents IP Group on the boards of a number of its portfolio companies, both quoted and private. He has been at IP Group since 2008 and has extensive experience in building world changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. Dr. Warne joined IP Group from pre clinical drug discovery contract research organisation, Exelgen, where he was Managing Director. He spent eight years at Exelgen (formerly known as Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. Dr Warne has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.
Prof. Lee Cronin
Founding Scientific Director
Professor Cronin is the Regius Chair of Chemistry in the Department Chemistry at the University. He was elected to the Fellowship of the Royal Society of Edinburgh, the Royal Society of Chemistry, and appointed to the Gardiner Chair in April 2009. He was awarded a Philip Leverhulme Prize by the Leverhulme Trust in 2007. He was awarded the Corday-Morgan medal of the Royal Society of Chemistry in 2012. Professor Cronin has a large active group at the University of Glasgow performing cutting-edge research into how complex chemical systems, created from non-biological building blocks, can have real-world applications with wide impact. Professor Cronin has published in excess of 300 peer-reviewed articles in a number of journals and has given over 280 invited presentations at conferences and universities worldwide.
Michael Bretherton is a chartered accountant having trained at PriceWaterhouse and acted as Finance Director in a number of public and private firms. His principal role from May 2006 to July 2014 was that of Finance Director of Channel Islands' based ORA Capital Partners Limited, an investment company with active interests in early stage growth companies. Mr. Bretherton is also Chairman of Sarossa plc which invests in technology companies.
James Ede-Golightly is chairman of East Balkan Properties Plc and Quoram Plc and has extensive experience as a non-executive on the boards of AIM-quoted companies with international business interests. James was a founder of ORA Capital Partners in 2006, having previously worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. He is a CFA Charterholder and holds an MA in economics from Cambridge University. In 2012, he was awarded New Chartered Director of the Year by the Institute of Directors.
Laurence Ede was the Managing Director and co-owner of Tocris Bioscience, a company producing chemical compounds for pharmaceutical research, when it was sold to Techne Corporation for £75M in 2011. Mr. Ede had previously led the Management Buyout of Tocris for £14M five years earlier and grew its value by focusing on developing the business to be an increasingly significant provider of products within the life science arena. Mr. Ede is currently a non-executive director of Ubiquigent Ltd, a drug discovery services company using research tools and chemistry to pursue ubiquitin system-focused drug discovery programmes. He has a BSc in Chemistry from Reading University and an MBA from the University of Bath.